Castle Biosciences (CSTL 4.37%), a developer of diagnostic tests supporting personalized treatment decisions in dermatology and gastroenterology, reported its second quarter 2025 results on August 4, 2025. The company significantly outperformed Wall Street expectations in Q2 2025, with GAAP EPS of $0.15 and non-GAAP revenue of$86.2 million, both exceeding analyst estimates. GAAP earnings per share reached $0.15, well above the consensus estimate of -$0.53. Non-GAAP revenue was $86.2 million, surpassing the ...